Shanghai S.E.
06:00:00 2024-05-12 pm EDT
5-day change
1st Jan Change
29.05
CNY
+0.21%
+1.57%
+20.14%
Mayinglong Pharmaceutical Group Co., Ltd. Announces Cash Dividend for the Year 2019, Payable on July 30, 2020
Mayinglong Pharmaceutical Group Co., LTD. implements the scheme of rights and interests distribution for 2019 as a cash dividend of RMB 0.26 (taxes included) per A share. Record date is July 29, 2020. Ex-dividend date is July 30, 2020 and Cash dividend payable date is July 30, 2020.
Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
Apr. 19
CI
Mayinglong Pharmaceutical Receives Registration Approval for New Colorectal Treatment
Apr. 17
MT
Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Apr. 12
CI
Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
23-10-27
CI
Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
23-08-25
CI
Mayinglong Pharmaceutical Group Co., LTD. Reports Earnings Results for the First Quarter Ended March 31, 2023
23-04-28
CI
Mayinglong Pharmaceutical Group Co., LTD. Reports Earnings Results for the Full Year Ended December 31, 2022
23-04-07
CI
Hangzhou Yunbai Pharmaceutical Technology Co., Ltd. agreed to acquire 86.816% of stake in Shenzhen Daphne Pharmaceautical Co.,Ltd from from Mayinglong Pharmaceutical Group Co., LTD., Huayi Development Co., Ltd., China Bao An Co., Ltd and Guofa Jianfu Industrial Co., Ltd. for approximately CNY 260 million.
22-12-13
CI
Mayinglong Pharmaceutical Group Co., LTD. Reports Earnings Results for the Nine Months Ended September 30, 2022
22-10-25
CI
Mayinglong Pharmaceutical Group Co., LTD. Reports Earnings Results for the Half Year Ended June 30, 2022
22-08-19
CI
Mayinglong Pharmaceutical Group Co., LTD. Reports Earnings Results for the First Quarter Ended March 31, 2022
22-04-26
CI
Mayinglong Pharmaceutical Group Co., LTD. Reports Earnings Results for the Full Year Ended December 31, 2021
22-03-22
CI
Mayinglong Pharmaceutical Group Co., LTD. Reports Earnings Results for the Nine Months Ended September 30, 2021
21-10-22
CI
Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021
21-08-20
CI
Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021
21-04-23
CI
Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020
21-03-25
CI
Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020
20-10-23
CI
Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2020
20-08-21
CI
Mayinglong Pharmaceutical Group Co., Ltd. Announces Cash Dividend for the Year 2019, Payable on July 30, 2020
20-07-21
CI
Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2019
20-04-24
CI
Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2020
20-04-24
CI
Mayinglong Pharmaceutical Group Co., Ltd. Provides Earnings Guidance for the Year 2019
20-01-20
CI
Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2019
19-10-23
CI
Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2019
19-08-23
CI
Mayinglong Pharmaceutical Group Co., Ltd Announces the Cash Dividend for 2018, Payable on July 26, 2019
19-07-17
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Mayinglong Pharmaceutical Group Co., Ltd. is a China-based company, principally engaged in pharmaceutical production, retailing and wholesaling businesses. The Company's pharmaceutical products are classified as drugs for hemorrhoid, including diosmin tablets, suppositories, pastes and granules, among others; drugs for cough, including levodropropizine oral solution and compound glycyrrhiza oral solution, as well as drugs for skin injuries, including products such as erythromycin ointment. The Company also provides specialty drugs. The Company is also engaged in the production and distribution of eye cream products with the brand named Mayinglong BaBao, as well as the provision of hospital clinical service. The Company distributes its products mainly in domestic markets.
More about the company
1st Jan change
Capi.
+20.14% 1.73B +21.09% 43.27B +25.39% 22.92B +19.22% 15.43B +13.51% 12.95B +44.01% 11.83B -6.70% 6.91B -0.05% 6.79B -8.87% 5.73B +13.26% 5.55B
Generic Pharmaceuticals
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
MAYINGLONG PHARMACEUTICAL GROUP CO., LTD. 
